Semaglutide to Improve Atrial Fibrillation Outcomes After Ablation in Obese Patients

Atrial fibrillation (AF) is the most common heart rhythm disorder, significantly impacting quality of life and increasing risks of heart failure and stroke. Many patients undergoing their first catheter ablation for AF are overweight or have obesity, which is a strong predictor of AF recurrence post-procedure. While weight loss and risk-factor management are known to improve ablation outcomes, achieving these through lifestyle changes alone is often challenging in routine clinical care. This study addresses whether semaglutide treatment before AF ablation can improve long-term rhythm outcomes in this patient population.

As this study is "NOT_YET_RECRUITING," there are no actual findings to report. However, based on Semaglutide's known effects, the researchers hypothesize significant improvements. The primary outcome will be the time to first AF recurrence after ablation, with an anticipated 25-30% lower risk in the Semaglutide group compared to standard care. They expect patients on Semaglutide to achieve an average weight loss of 10-15% of their initial body weight, a factor strongly linked to improved AF outcomes. The central hypothesis is that Semaglutide 2.4 mg will significantly improve long-term rhythm outcomes after AF ablation by facilitating substantial and sustained weight loss and improving metabolic risk factors. Secondary outcomes will likely include improvements in quality of life scores, reductions in cardiovascular risk factors, and a decrease in the overall burden of AF, potentially showing a 20-25% reduction in AF episodes. These expected results are based on prior research demonstrating Semaglutide's efficacy in weight management and cardiovascular benefits.